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ABSTRACT
Inhalational anesthetic agents are chemi-
cal substances that are administered into 
the body via lungs and distributed to or-
gans and tissues by blood circulation. 
!e main site of their action is the brain, 
but they also a"ect other parts of central 
nervous system. Volatile and intravenous 
anesthetics alike have nearly reached the 
characteristics of an ideal anesthetic, but 
at a #rst glance, the increase in use of in-
travenous anesthetics could likely push out 
their volatile counterparts. Looking at the 
situation more thoroughly, positive side 
e"ects of volatile anesthetics that are not 
found in their intravenous counterparts, 
still give them a place in modern anesthe-
sia practice. It is also possible to combine 
both techniques to reduce negative adverse 
e"ects, while making use of the positive 
ones.
INTRODUCTION
Inhalational anesthetic agents are chemical 
substances administered into the body via 
lungs and distributed to organs and tissues 
by blood circulation. !e main site of their 
action is the brain, but they also a"ect oth-
er parts of central nervous system. In the 
brain, they act on the membranes of neu-
rons. !ey can facilitate inhibitory func-
tions or attenuate excitation of neurons, 
which can result in general anesthesia.
!e characteristics of an ideal anesthetic 
agent should include: rapid induction and 
emergence, simple use, su$cient analgesia, 
inhibition of re%exes and relaxation of stri-
ated muscles, safety and absence of toxic 
adverse e"ects.
Volatile anesthetics used today have come 
close to the above described criteria, but 
do not ful#ll them completely just yet. For 
these reasons, we combine them with oth-
er medications (intravenous anesthetics, 
opioids, nitrogenous oxide, muscle relax-
ants). Most o&en, we use them in so called 
“balanced anesthesia”. !is way, safety is 
increased, while negative adverse e"ects 
are decreased.
Recently, TCI (target-controlled anesthe-
sia) with intravenous anesthetics is being 
used more and more. It would appear that 
intravenous anesthetics are going to com-
pletely push out the volatile anesthetics 
that had been used a lot in the past. But is 
this really going to happen?
 
IS THE NONSPECIFIC MECHANISM OF 
ACTION THE MAIN ADVANTAGE OF 
VOLATILE ANESTHETICS? 
Intravenous anesthetics in use today, such 
as propofol and etomidate, work mainly 
by acting on GABA receptors. Relatively 
high selectivity of these compounds is ap-
parent, when replacing one amino acid 
in the GABA receptor. !at can already 
counter the e"ects of an intravenous an-
esthetic. Because of this high selectivity, 
intravenous anesthetics have generally less 
adverse e"ects in comparison to volatile 
anesthetics. !ere is also a possibility for 
development of selective antagonists, such 
as %umazenil for benzodiazepines.
High selectivity is not necessarily an ad-
vantage, though. For example, a minor 
mutation in a patient could decrease e$-
cacy of intravenous anesthetic. Such muta-
tions had already been proven. Expression 
of GABA receptor itself, for example in al-
cohol consumption or neurologic disorder, 
could also change the sensitivity for an in-
travenous anesthetic. In volatile anesthet-
ics we do not encounter such phenomena. 
Even though they act on GABA receptors 
as well, they produce anesthesia by acting 
on di"erent sites. If it turns out, that when 
propofol is not e$cient in a patient, vola-
tile anesthetics present an excellent alter-
native and can produce su$cient depth of 
anesthesia (1).  
!ere is also a di"erence between volatile 
and intravenous anesthetics in their e"ect 
on nociceptive and other neural pathways 
in the spinal cord. Intravenous anesthetics 
ensure good anesthesia and amnesia, but 
they do not a"ect other structures in the 
spinal cord. Increased intake of propofol 
does not result in increased muscle relaxa-
tion, as opposed to volatile anesthetics. 
!at results in more frequent muscle con-
tractions and movements with propofol. 
Intravenous anesthetics possibly inhibit 
spinal neurons that express GABA. !is 
could increase excitability of spinal neural 
networks. Studies have shown that volatile 
anesthetics attenuate motor response to 
pain stimulus via glycine receptors. Gly-
cine is, in fact, one of the main actors in 
spinal pain processing. Volatile anesthetics 
are the only substances that have a modu-
latory e"ect on glycine receptors in clini-
cally relevant doses (1).
It is also very desirable for a modern an-
esthetic to work by attenuating pain in 
the spinal cord aside from its anesthetic 
and anamnestic properties. !at could de-
crease the chance of hyper-sensibilization 
and chronic pain development (1).
!ese characteristics could make volatile 
anesthetics model compounds for devel-
opment of new intravenous anesthetics. 
Modern intravenous anesthetics should, 
aside from their action on GABA recep-
tors, in%uence the glycine receptors as well. 
Such anesthetic agents are already being 
developed in laboratories.
Development of intravenous agents that 
would work less speci#cally and on mul-
tiple di"erent receptors contradicts the 
principle that anesthetic substances should 
have a speci#c mechanism of action (2). 
In the past, highly selective substances 
had been synthetized, but have resulted 
in unexpected consequences (3, 4). A pos-
sible reason for that in biologic organisms 
could lie in their need for stability, result-
SIGNA VITAE 2019; 15(2): 14-17
       SIGNA VITAE    |    15
ing in development of multiple copies 
of signaling pathways or production of 
compensatory mechanisms to counter the 
external disturbance. A more recent view 
in development of the new medications is 
not concentrated on highly selective drugs 
that would work on a speci#c receptor any-
more but rather on developing substances 
that trigger the molecular mechanism and 
work on interactions of signaling path-
ways- i.e. network pharmacology (4, 5).
IMMUNOMODULATORY ACTION OF 
VOLATILE ANESTHETICS
Another reason for usage of volatile anes-
thetics is their bene#cial immunomodula-
tory and anti-in%ammatory e"ect.  Many 
studies have shown that volatile anesthet-
ics reduce systemic and local in%ammatory 
response during major surgery (6, 7).
Cellular- protective e"ects of volatile an-
esthetics had #rst been proven in cardio-
vascular surgery. Volatile anesthetics have 
proven cardio-protective e"ect and have 
been applied for pre-and post-condition-
ing in open cardiac surgery with extracor-
poreal circulation (8).
Later, evidence of volatile anesthetics’ ben-
e#cial e"ects had emerged in other surgi-
cal #elds as well. In UMC Ljubljana, Jerin 
et al. showed decreased perioperative in-
%ammation, when using volatile anesthet-
ics in patients undergoing liver surgery (9).
Perioperative in%ammatory response is 
dependent mainly on the type of anes-
thetic substance used. Lahat and McBridge 
showed in their studies, increased levels 
of cytokines in the blood immediately fol-
lowing induction, before the beginning 
of surgical procedure (10, 11). Studies on 
cell cultures implied, that intravenous an-
esthetics encourage in%ammatory cells to 
produce cytokines (12). Intravenous anes-
thetics inhibit polarization of neutrophils 
and chemotaxis to a greater extent than 
their volatile counterparts. (13) Anesthet-
ics do not only change non-speci#c, but 
also speci#c immune response by a"ecting 
proliferation, lymphocyte count and levels 
of immunoglobulins in blood (14). 
Limited animal data have suggested that 
volatile anesthetics can induce neuro-in-
%ammation, which leads to the decline of 
cognitive function in rodents. !is e"ect is 
yet to be veri#ed in humans (15).  How-
ever, volatile anesthetics have been shown 
to accelerate post-ischemic neurogenesis, 
suggesting that they may also enhance 
endogenous reparative processes in the in-
jured brain (16).
ANESTHETICS AND INFLAMMATORY 
RESPONSE 
In general, anesthetic agents cause an in-
crease in production and levels of leuko-
cytes in blood (17). Every anesthetic a"ects 
a di"erent type of immune cells (Table 1) 
(17).
Anesthetic agents also a"ect perioperative 
immune response with their e"ect on syn-
thesis and excretion of cytokines and glu-
cocorticoids (Table 2) (17). 
General anesthetics and in%ammation 
Propofol reduces production of pro-in-
%ammatory cytokines, alters expression of 
nitric oxide, and inhibits neutrophil func-
tion (18). Researchers have been studying 
pro-in%ammatory e"ects of propofol for 
a long time, but so far, no published study 
has yet con#rmed it. In%ammation could 
be a result of apolipoprotein A-1 modula-
tion. Ricou was the latest to start a study 
that would explore this, but there have 
been no published results yet (19-21). 
Aside from anesthesia, volatile anesthetics 
have other e"ects. Of those, inhibition of 
in%ammatory response is especially im-
portant and bene#cial (22). !at was #rst 
shown by in vitro studies on animals (23). 
Subsequent clinical studies have con#rmed 
that, at #rst in the #eld of cardiac surgery. 
It was proven that sevo%urane, when used 
in extracorporeal circulation, decreases 
expression of antigen receptor in granu-
locytes and polymorphonuclear (PMN) 
cells. Following studies showed decreased 
blood levels of pro- in%ammatory cy-
tokines (especially TNF-α, IL-6 and IL-8) 
a&er using extracorporeal circulation (24). 
A study from this #eld was undertaken in 
Slovenia as well and it con#rmed the bene-
#cial e"ect of volatile anesthetics in cardiac 
surgery (25). 
Anti-in%ammatory characteristics of vola-
tile anesthetics had also become a point 
of interest in the #eld of thoracic surgery, 
where postoperative pulmonary in%am-
mation is the main reason of periopera-
tive morbidity and mortality. Studies have 
shown bene#cial e"ects of volatile anes-
thetics in sense of postoperative in%amma-
tion decrease and decrease of postopera-
Table 1. General anesthetics and their e,ect on immune cells.
Immune cell E!ect
Leukocytes sevo%urane Ĺ cell count, des%urane Ĺ cell count, propofol Ĺ cell count, 
iso%urane Ĺ cell count 
Neutrophiles thiopental Ļ phagocytosis,  propofol Ļ phagocytosis Ĺ cell count, 
iso%urane Ļ phagocytosis,  des%urane Ĺ cell count
Mononuclear 
phagocytes
sevo%urane Ļ monocyte count, halothan Ĺ phagocytosis Ļ cell count, 
propofol Ļ phagocytosis , midazolam Ļ phagocytosis, thiopental Ļ 
phagocytosis 
Lymphocytes propofol Ļ cell count, sevo%urane Ļ cell count, iso%urane Ļ cell count, 
ketamine Ļ proliferation
Natural killer cells propofol Ĺ cell count, Ļ cytotoxic activity sevo%urane Ĺ cell count, 
des%urane Ĺ cell count, iso%urane Ļ cell count, halothane Ļ cytotoxic 
activity 
CD4 T-helper cells halothane Ļ cell count, sevo%urane Ļ cell count, iso%urane Ļcell 
count, propofol Ĺ cell count 
CD8 cytotoxic 
T-lymphocytes
propofol Ļ cell count, sevo%urane Ļ cell count, halothane Ļ cell count, 
iso%urane Ĺ cell count, des%urane Ĺ cell count, iso%urane Ĺ apoptosis
CD19 B-lymphocytes iso%urane Ĺ cell count, des%urane Ĺ cell count , halothane Ĺ antibody 
titre, sevo%urane Ĺ primary and secondary immune response
Table 2. E,ects of general anesthetics on cytokine synthesis.
Cytokine E!ect on plasma levels 
IL-1 propofol Ļ, ketamine Ļ, thiopental Ļ, iso%urane Ĺ, sevo%urane Ļ, des%urane Ļ 
IL-6 propofol Ĺ, ketamine Ļ, thiopental Ļ, remifentanil Ĺ, sevo%urane Ĺ,  iso%urane Ĺ 
IL-8 ketamine Ļ, propofol Ĺ , thiopental Ļ, midazolam Ļ, iso%urane Ĺ , propofol in 
vitro Ļ excretion from neutrophiles 
IL-10 ketamine Ĺ , propofol Ĺ , thiopental Ĺ, iso%urane Ĺ, sevo%urane Ĺ 
TNF-α ketamine Ļ, propofol Ļ, thiopental Ļ, iso%urane Ĺ, sevo%urane Ļ, en%urane Ļ 
16   |  SIGNA VITAE
tive complications (26).
On the other hand, study on patients un-
dergoing craniotomy showed that propo-
fol based anesthesia was associated with 
signi#cantly higher anti-in%ammatory 
cytokine IL-10 levels than anesthesia with 
sevo%urane. !ese #ndings, however, seem 
to have little e"ect on outcome, since nei-
ther sevo%urane nor propofol had any 
signi#cant impact on the occurrence of 
postoperative complications (27). !ere-
fore, in general, it is possible to assert that 
inhalational and intravenous anesthetic 
agents, obviously with some minor ex-
ceptions, might play an important role in 
terms of neuroprotection during surgical 
procedures. Nevertheless, data seem to be 
insu$cient to recommend any speci#c an-
esthetic agent as the optimal neuroprotec-
tive agent (28).
CONCLUSION
At present, available experimental data do 
not support the selection of any one anes-
thetic agent over the others. Modern in-
travenous anesthetic agents are substances 
that get very close to a theoretical ideal an-
esthetic, but volatile anesthetics still hold a 
place in modern anesthesia practice. Aside 
from anesthesia and amnesia they also have 
analgesic properties and muscle relaxant 
e"ect. !eir bene#cial immunomodula-
tory e"ect and anti-in%ammatory e"ect is 
desirable especially in major surgical pro-
cedures, linked to substantial systemic in-
%ammatory response in the perioperative 
period. Lastly, both anesthetic techniques 
can be combined (intravenous and inhala-
tional anesthesia). !at increases the desir-
able e"ects of both agents, while decreas-
ing their adverse e"ects. 
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